多巴胺D_(2/3)受体和5-HT_(1A)受体部分激动剂卡利拉嗪的药理作用和临床评价  

Pharmacological and clinical evaluation of cariprazine-dopamine D_(2/3) and 5-HT_(1A) receptor partial agonist in the treatment of schizophrenia and major depressive disorder

作　　者：徐磊[1,2] 李静华[3] 封宇飞[2] XU Lei LI Jing-hua FENG Yu-fei(School of Life Science and Biopharmaceutics , Shenyang Pharmaceutical University, Shenyang 110016, China Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Beifing lO0730,China Department of Pharmacy,Zhengzhou Central Hospital,Zhengzhou University, Zhcngzhou 450007, China)

机构地区：[1]沈阳药科大学生命科学与生物制药学院,沈阳110016 [2]北京医院药学部国家老年医学中心,北京100730 [3]郑州大学附属郑州市中心医院药剂科,郑州450007

出　　处：《中国新药杂志》2017年第3期250-253,共4页Chinese Journal of New Drugs

摘　　要：卡利拉嗪是一种新型的、多巴胺D_(2/3)受体和5-HT_(1A)受体部分激动剂,主要用于精神分裂症以及双相Ⅰ型情感障碍相关的躁狂急性发作或混合发作的治疗。本品最常见的不良反应为锥体外系症状,如静坐不能、颤动、呕吐和失眠等。本文对其药理作用、药动学、临床评价、安全性、用法用量和药物相互作用进行综述。Cariprazine is a novel dopamine D3 and D2receptor partial agonist which is indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. It is also a partial agonist at 5-HT1 Areceptor. The most common adverse events were extrapyramidal symptoms,for instance akathisia,tremor,vomiting and insomnia. The pharmacology,pharmacokinetics,clinical research,safety,dosage,and drug interactions were reviewed in this paper.

关 键 词：卡利拉嗪 精神分裂症 双相Ⅰ型情感障碍 多巴胺D2/3受体部分激动剂 5-HT1A受体部分激动剂 药理作用 临床评价 

分 类 号：R971.4[医药卫生—药品]